Journal article
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: The FIELD study
RD Ting, AC Keech, PL Drury, MW Donoghoe, J Hedley, AJ Jenkins, TME Davis, S Lehto, D Celermajer, RJ Simes, K Rajamani, K Stanton
Diabetes Care | AMER DIABETES ASSOC | Published : 2012
DOI: 10.2337/dc11-1109
Abstract
OBJECTIVE - Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m 2) are at particular cardiovascular risk. Fenofibrate's safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. RESEARCH DESIGN AND METHODS - Type 2 diabetic patients (aged 50-75 years) with eGFR>30 mL/min/1.73 m 2 were randomly allocated to a fixed dose of fe..
View full abstractGrants
Funding Acknowledgements
The FIELD Study was supported by grants from Laboratoires Fournier SA, Dijon, France (now part of Abbott Pharmaceuticals), and the National Health and Medical Research Council (NHMRC) of Australia.R.-D.T., A.C.K., T.M.E.D., R.J.S., and K.R. have received speaker's bureau fees from Solvay (now Abbott Pharmaceuticals). A.C.K., P.L.D., A.J.J., T.M.E.D., and R.J.S. have received travel and/or research grant support from Solvay (now Abbott Pharmaceuticals). No other potential conflicts of interest relevant to this article were reported.